Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Inclusion Criteria:

• Male or female subjects aged ≥18 years

• Subjects with suspected or known CAD based on signs and/or (typical or atypical) chestpain who have routine CA without intervention within plus/minus 4 weeks ofgadobutrol-enhanced CMRI or subjects at low risk of CAD with / or scheduled to get aCTA for the purpose of exclusion of CAD within plus/minus 6 weeks ofgadobutrol-enhanced CMRI

• Willingness to undergo unenhanced wall motion and gadobutrol-enhanced CMRI atstress/rest and gated single photon emission computed tomography (GSPECT, if GSPECTwill be a study procedure)

• Women of childbearing potential (e.g. age < 60y, no history of surgical sterilizationor hysterectomy): use of contraception and a negative pregnancy test

• Subjects who are scheduled for / have undergone routine GSPECT or undergo GSPECT as astudy procedure at stress and at rest within ± 4 weeks of gadobutrol-enhanced CMRI

Exclusion Criteria:

• Suspected clinical instability or unpredictability of the clinical course during thestudy period

• Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severeclaustrophobia, metallic devices such as pace makers)

• History of severe allergic or anaphylactoid reaction to any allergen including drugsand contrast agents according to the investigator's assessment / judgment

• Estimated glomerular filtration rate (eGFR) value <30 mL/min/1.73 m^2 derived from aserum / blood creatinine result within 2 weeks prior to gadobutrol injection. Anysubject on hemodialysis or peritoneal dialysis is excluded from enrollment.

• Acute renal insufficiency

• Coronary artery bypass grafting (CABG)

• Acute myocardial infarction (< 14 days prior to inclusion), unstable angina / acutecoronary syndrome, severe congestive heart failure

• Irregular heart rhythm

• Condition that precludes the safe administration of pharmacological stressor accordingto the respective approved label such as sinus node disease, 2nd or 3rd degreeatrioventricular block, obstructive lung disease